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Abstract
Objectives: The present study was conducted to raise attention to the frequency of Candida spp. and evaluation of risk factors of
candidemia in hospitalized neonates and children.
Methods: Identification of Candida at species level was done using the PCR-RFLP method. The Candida albicans complex and Can-
dida parapsilosis complex were differentiated using the HWP1 gene amplification and PCR-RFLP with NlaIII restriction enzyme, re-
spectively.
Results: Out of 75 blood culture specimens, 42 (84%) cases were positive for Candida spp. of whom 30 (71.42%) and 12 (28.57%) cases
were female and male, respectively. Thirty-two (76%) candidemia were presented in pediatrics with 6 years up to 12 years, 10 (23.80%)
in neonates of one month or less. In the present study, Candida parapsilosis (n =25; 59.52%) was the most prevalent isolated species
followed by C. albicans (n =11; 26.19%), C. tropicalis (n =4; 9.52%), and Candida glabrata (n =2; 4.76%).
Conclusions: According to potentially dangerous complications of bloodstream infection by Candida spp. in neonates and chil-
dren, it is necessary to identify and eliminate the underlying conditions and risk factors of this disease.
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1. Background
Candidemia in neonates and children can lead to se-
vere morbidity, and it can be even fatal despite appro-
priate treatment (1). According to the literature, the epi-
demiologic pattern and frequency of pediatric candidal
infection differs from adults (2); thereby needing com-
prehensive strategies to the management of candidemia
(2). Candida spp. is known as the third to fourth most
common pathogen cause of nosocomial bloodstream in-
fections (BSI) (3, 4). This destructive infection is mainly
caused by, Candida albicans (5, 6). Currently, the epidemi-
ology of the candidemia is changing, and we are facing
the emergence of non-C. albicans (NAC) spp., including Can-
dida parapsilosis, Candida tropicalis, Candida glabrata, and
Candida krusei (7). Candida parapsilosis is considered the
predominant causative agent of candidemia in pediatric
oncologic disorders (2). Differences in Candida spp. are
related to disease severity and diversity in antifungal sus-
ceptibility, patterns; therefore, understanding the type of
species is clinically important.
Only limited information about burden of infection
and risk factors are available in neonates and pediatrics in
Iran and further study is required to address its burden (5,
6, 8-10).
2. Objectives
The present study was conducted to raise attention to
the frequency of Candida spp. and evaluation of risk factors
in hospitalized neonates and children that were suspected
of having invasive candidiasis (IC).
3. Methods
3.1. Study Areas and Subjects
This cross-sectional study was conducted from 2017 to
2018. The blood samples were obtained from each patient
using a sterile syringe and directly infused into biphasic
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blood media. Seventy-five blood culture samples were col-
lected from neonates and children≤ 14 years old who were
hospitalized and suspected of fungal infection. Bacterial
positive samples were excluded from the study.
3.2. Conventional Identification
Blood samples were inoculated into aerobic culture
medium bottles (BACTEC Peds Plus/F Culture Vials, Ireland)
followed by incubation for a period of 5 days in the auto-
mated blood culture system BACTEC 9120 (Becton Dickin-
son, Spark, MD, USA). The candidemia was defined as hav-
ing more than one positive culture specimen. Each episode
of IC was considered a new case if at least one month would
have been passed from a previously treated occurrence
(3). The positive cultures were subcultured on blood agar
(Merck, Darmstadt, Germany) at 35°C and checked each
day for up to five days. To access the pure colony, the pos-
itive cultures were subcultured on CHROMagar (CHROMa-
gar Paris, France) at 35°C for 24 hours.
3.3. Molecular Identification
All isolates were cultured on yeast extract peptone dex-
trose (YEPD) agar (Merck, Germany) at 37°C for 24 hours.
DNA was extracted using the genomic DNA extract kit (Ge-
neAll, Korea).
Definite identification of Candida spp. was confirmed
by the PCR-restriction fragment length polymorphism
(RFLP) approach based on the amplification of ITS1-5.8
SrDNA-ITS2 region with pun fungal primers ITS1-ITS4 that
were synthesized by Bioneer Company (Korea) and en-
zymatic digestion. The PCR was conducted with a mix-
ture included 1 µL of extracted DNA, 10 µL of Taq DNA
Polymerase Master Mix RED (Ampliqon, Denmark), 1 µL
of each ITS1 (5’-TCCGTAGGTGAACCTGCGG-3’) and ITS4 (5’-
TCCTCCGCTTATTGATATGC -3’) pair primers (11), H2O up to
25 µL. The PCR program as follow as; 95°C for 5 minutes,
35 cycles of denaturation for 5 minutes at 94°C, anneal-
ing for 1 minute at 58°C, an extension for 1 minute at 72°C,
with a final extension of 7 minutes at 72°C. The ampli-
cons were visualized using 1.5% agarose gel electrophore-
sis in TBE buffer (Merck, Germany) and stained with safe
stain (Waltham, USA). The products were subjected to the
MSP1 restriction enzyme (Fermentas, USA). Restriction frag-
ments were separated by 2% agarose gel electrophoresis
for 1 hour. The C. albicans complex and C. parapsilosis com-
plex were differentiated using the HWP1 gene amplification
and PCR-RFLP with NlaIII restriction enzyme, respectively
(12, 13). The PCR program was similar to ITS1-5.8 SrDNA- ITS2
PCR with a minor difference in annealing temperature.
4. Results
Out of 75 blood cultures, 42 (84%) cases were positive
for Candida spp. growth of whom 30 (71.42%) were female,
and 12 (28.57%) were male. Thirty-two (76%) candidemia
were presented in pediatrics with 6 years up to 12 years,
10 (23.80%) in neonates of one month or less. The patients
had received several wide-spectrum antibiotics. There was
evidence of empiric antifungal treatment based on medi-
cal records, including caspofungin, voriconazole, ampho-
tericin B and it was not qualified for antifungal therapy.
Nineteen (45.23%) of pediatrics had hematological malig-
nancy and 2 (7.1%) had heart disease and remains had other
non-leukemia related disease or neonate. The evidence of
neutropenia, low weight < 1500, long-stay hospitalization,
chemotherapy, history of surgery, central venous catheters
(CVC) use were also seen.
The amplification pattern of the ITS1-5.8 SrDNA-ITS2 re-
gion of Candida spp. using the ITS1-ITS4 primers is shown
in Figure 1. Subsequently, all isolates were subjected to the
digestion by MSP enzyme to precise identification (Figure
2). All of the C. albicans complex strains were identified as
C. albicans with HWP1 gene primers (Figure 3).
Figure 1. The amplification pattern of ITS1-5.8 SrDNA-ITS2 region of Candida spp. us-
ing the pun fungal primers. M: 100 bp DNA size marker.
In the present study, C. parapsilosis (n = 25; 59.52%) was
known as the most prevalent isolated species followed by
C. albicans (n = 11; 26.19%), C. tropicalis (n = 4; 9.52%), C.
glabrata (n = 2; 4.76%) (Figure 4).
5. Discussion
The number of uncommon Candida spp. isolated from
clinical samples is increasing, and invasive candidiasis (IC)
caused by these species may paradoxically be the result of
advances in medical care (6). Regarding higher resistance
to fluconazole and echinocandins in non-albicans Candida
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Figure 2. RFLP pattern with MspI restriction enzyme: A, C. albicans (297 - 238 bp): 1, 3; C. glabrata (314 - 557 bp): 2; C. tropicalis (184 - 340 bp): 4; B, C. parapsilosis (520 bp):5. M: 100
bp DNA size marker.
Figure 3. The amplification pattern of HWP1 genes in C. albicans complex. M: 100 bp
DNA size marker.
Figure 4. Agarose gel electrophoresis of RFLP-PCR products of C. parapsilosis after
digestion with NlaIII. Lane M, 100 bp DNA size marker; lane 1, C. parapsilosis ATCC
22019 without effect enzyme (716 bp); lanes 2 - 8 are C. parapsilosis (131 and 505 bp).
spp. (NAC), identification of Candida spp. is necessary for
appropriate management of infection.
As mentioned before, the studied population had sev-
eral risk factors for developing candidemia. In the present
study, C. parapsilosis (n = 25; 59.52%) known as the most
prevalent isolated species followed by C. albicans (n = 11;
26.19%), C. tropicalis (n = 4; 9.52%), and C. glabrata (n = 2;
4.76%). These findings were consistent with previous re-
ports that indicated C. parapsilosis complex was considered
the predominant causative agent of candidemia in both
neonates and pediatrics (5, 9, 10, 12, 13). In some multicen-
ter studies, C. albicans was considered the most frequent
species in pediatrics (6, 8, 10).
Regarding the risk factors, there was no significant dif-
ference between the two groups of candidiasis by C. albi-
cans and NAC (P < 0.01). A study by Juster-Reicher et al.
also revealed no difference between the two groups with
candidemia caused by C. albicans and C. parapsilosis (P <
0.01) (14) considering the risk factors such as CVC, onco-
logic disorders, and chemotherapy. However, there are sev-
eral studies showing a higher frequency of bloodstream in-
fections caused by C. parapsilosis in CVC usage (5, 12, 15-17).
In contrast to the pediatric population, low birth weight
(LBW), and very low birth weight (VLBW) neonates were
more associated with candidemia caused by C. parapsilosis
(16, 18).
In contrast to previous studies (6, 19) in pediatric
C. tropicalis is the third common strains were isolated
in candidemia in the present study. In line with previ-
ous research, further analyses revealed that C. tropicalis
candidemia has been associated with neutropenia and
leukemia (20).
C. glabrata is rarely seen in neonates and children.
However, in a study performed on immunocompromised
children, C. glabrata was isolated as the second frequent
cause of candidemia (19). Contrary to Charsizadeh et al.
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study (6), we did not isolate C. glabrata in blood samples
in the neonatal intensive care unit (NICU). Two C. glabrata
strains were isolated in patients suffering from acute lym-
phoblastic leukemia (ALL), the later admitted in pediatric
intensive care unit (PICU) and both of them had CVC. Kara
et al. (18) isolated C. glabrata from pediatrics that had in-
fective endocarditis. In a study from Australia, neonates
had a higher rate (9.1%) than pediatrics (10). Since Candida
spp., which were once considered to be harmless, can now
cause candidemia and significant morbidity and mortality
in patients residing in intensive care units, identifying the
underlying conditions and risk factors must be noticed se-
riously. Candida bloodstream infection might be the result
of selective pressure of some antifungal agents, previous
wide spectrum antibacterial therapy, multiple intravascu-
lar catheters, parenteral nutrition, and mechanical venti-
lation. However, some studies found no relationship be-
tween Candida serotypes and underlying diagnosis, risk
factors, clinical features, and outcomes (20-23).
5.1. Conclusions
According to potentially dangerous complications of
bloodstream infection by Candida spp. in neonates and
children, it is necessary to identify and eliminate the un-
derlying conditions and risk factors of this disease within
an appropriate framework.
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